Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology

Nivolumab monotherapy is approved as adjuvant treatment for melanoma based on results from the pivotal CheckMate 238 trial. We present a model‐based, benefit–risk assessment of nivolumab in adjuvant melanoma supporting a posology change from a weight‐based to a less frequent, flat‐dosing regimen. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghavi, Kinjal, Vuppala, Pradeep, Ivaturi, Vijay, Hamuro, Lora, Roy, Amit, Suryawanshi, Satyendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302247/
https://www.ncbi.nlm.nih.gov/pubmed/33955714
http://dx.doi.org/10.1002/psp4.12642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302247/
https://www.ncbi.nlm.nih.gov/pubmed/33955714
http://dx.doi.org/10.1002/psp4.12642

Ejemplares similares